← Todos los textos
La idea clave: Leer para aprender

Un texto informativo explica un tema con datos, ejemplos y explicaciones. Cada párrafo suele tener una oración principal que el resto apoya.

Palabras clave

Significado de una palabra
Usa las palabras de alrededor para saber qué significa aquí.
Detalle
Un dato que el texto dice directamente. Vuelve a buscar la oración.
Inferencia
Algo que el texto no dice, pero las pistas muestran. Pista + lo que sabes = inferencia.
Idea principal
De qué trata sobre todo el texto entero, no solo una parte.

🔎 En qué fijarte: Lee la primera oración de cada párrafo para tener el mapa y vuelve al párrafo correcto para los detalles.

Editing Life: The Promise and Peril of CRISPR

12.º grado · Artículo · 973 palabras
Velocidad

In 2012, scientists described a way to edit DNA with unprecedented precision. The tool, known as CRISPR-Cas9, was adapted from a defence system that bacteria use against viruses. When a virus attacks a bacterium and fails, the bacterium stores a snippet of the virus's genetic code in its own DNA, like a mugshot. If the same virus returns, the bacterium produces a guide molecule that matches the mugshot and sends an enzyme, Cas9, to find and cut the invader's DNA. Researchers realized that by writing their own guides, they could send Cas9 almost anywhere in almost any genome.

In simple terms, it works like a pair of molecular scissors guided by a GPS: a short piece of RNA leads an enzyme to a specific location in the DNA, where it makes a cut. The cell's own repair processes then fix the break, and scientists can use that moment to disable a gene or insert a new sequence. Earlier gene-editing methods existed, but they were slow, expensive and difficult to design. CRISPR was cheaper, faster and far easier to use, and within a few years, laboratories around the world had adopted it. In 2020, Jennifer Doudna and Emmanuelle Charpentier received the Nobel Prize in Chemistry for this work, the first time two women had shared the prize without a male co-winner.

The possibilities are remarkable. Researchers are using CRISPR to develop treatments for inherited blood disorders such as sickle cell disease, a condition in which red blood cells take on a stiff, curved shape, block blood vessels and cause severe pain and organ damage. In 2023, regulators in several countries, including the United Kingdom and the United States, approved the first CRISPR-based therapy for it. Doctors remove a patient's own blood stem cells, edit them in the laboratory so they produce a healthier form of hemoglobin, and return them to the patient. Some patients who had been hospitalized repeatedly every year have gone years without a crisis.

Scientists are also exploring crops that resist drought or disease, mushrooms that do not brown, and livestock less vulnerable to infection. Newer versions of the technology, called base editing and prime editing, can change a single letter of the genetic code without cutting both strands of DNA, which may make edits safer and more precise. Researchers are studying how genes contribute to conditions ranging from cancer to blindness, and some trials are testing whether edits can be made directly inside the body rather than in cells removed from it.

Yet the same power raises profound ethical questions. A crucial distinction is between somatic editing, which changes the cells of one patient and is not inherited, and germline editing, which alters embryos, eggs or sperm so that changes pass to future generations. Somatic editing resembles other medical treatments: a patient, or a parent on a child's behalf, can weigh the risks and benefits. Germline editing is different. It affects people who do not yet exist and cannot consent, and any mistake could be passed down indefinitely.

In 2018, a researcher in China announced the birth of twin girls whose embryos he had edited, claiming he had tried to make them resistant to HIV. The announcement was widely condemned by scientists around the world, and he was later imprisoned. Critics argued that the procedure was unsafe, medically unnecessary, since there were already safe ways to prevent HIV transmission from parent to child, and carried out without proper oversight or truly informed consent. Analysis suggested the edits had not worked exactly as intended, and no one knows what long-term effects they may have.

Safety is not the only concern. CRISPR can sometimes cut DNA in the wrong place, and the long-term consequences of edits are still being studied. Cost matters too: the first approved sickle cell therapy was priced at around two million US dollars per patient, while most people with the disease live in sub-Saharan Africa and India, where few could afford it. A cure that reaches only the wealthiest countries raises questions of global justice.

Beyond safety and cost, there are concerns about fairness and the future of human diversity. If genetic enhancements, not just treatments, ever became possible, would they be available only to the wealthy, deepening inequality across generations? Who decides which traits count as a "disorder"? Many people in disability communities have warned that such decisions could reinforce the idea that some lives are less valuable than others. Some Deaf people, for example, describe deafness not as a defect to be eliminated but as part of a culture with its own language and history.

Scientists have faced similar questions before. In 1975, researchers gathered at Asilomar, in California, to set voluntary rules for an earlier genetic technology, and many have since called for a similar global conversation about CRISPR. Most scientific organizations currently support continued research on somatic therapies under strict regulation, while calling for great caution, or a pause, on heritable germline editing. Many countries prohibit it by law.

Some of the most hopeful stories involve the rarest diseases, which affect too few people for companies to develop treatments. In 2025, doctors in Philadelphia reported treating a baby born with a rare and often fatal liver disorder using a gene-editing therapy designed specifically for him, built and tested in about six months. The edit was delivered directly into his body, not into cells removed from it. It was a single case, and doctors stressed that he would need years of follow-up. But it raised a striking possibility: treatments made to order for a single patient. It also raised new questions about cost, testing and who would get access to such personal medicine.

As the technology advances, the questions it raises are not only scientific. They involve medicine, law, economics, religion and our ideas about what it means to be human. They belong to everyone.

Preguntas

Significado de una palabra 1. What does the comparison to "molecular scissors guided by a GPS" help explain?
Detalle 2. What is the difference between somatic and germline editing?
Leer entre líneas 3. Why was the 2018 announcement so widely condemned?
Leer entre líneas 4. Why does the author raise the question "Who decides which traits count as a 'disorder'?"
Idea principal 5. What is the author's overall stance?
Detalle 6. How did bacteria originally use the system that became CRISPR?
Leer entre líneas 7. Why does the author mention the price of the first sickle cell therapy and where most patients live?
Leer entre líneas 8. Why is consent a particular problem for germline editing?
Zero2Hero — Zéro2Héros